READ ME File For Dataset to support the thesis entitled "B-Cell receptor induced autophagy and phagocytosis in chronic lymphocytic leukaemia" Dataset DOI: 10.5258/SOTON/D2139 ReadMe Author: Annabel Rachel Minton, University of Southampton ORCID ID 0000-0002-2640-990X This dataset supports the thesis entitled AWARDED BY: Univeristy of Southampton DATE OF AWARD: 04/04/2022 This dataset contains: All figures presented in the thesis in an accessible format, including immunoblots, confocal microscopy data and graphed results. Additionally, the RNA-seq data underpinning the thesis is presented as log fold changes between control antibody and anti-IgM treated samples, with and without pre-treatment with VPS34-IN1, as detailed in the thesis. There are also results generated in IPA using the RNA-seq data included. The RNA-seq data is currently undergoing publication, but will also be available at ArrayExpress (www.ebi.ac.uk/arrayexpress) under accession E-MTAB-11195 once the publication has been processed. DESCRIPTION OF THE DATA anti-lgM bead phagocytosis video: Method: Cells were collected following experimental conditions and fixed in 4% paraformaldehyde solution for 15 minutes on ice. Permeabilisation was carried out in 0.25% Triton/PBS for 10 minutes at room temperature where required for intracellular stains. Cells were then incubated in relevant primary antibody overnight at 4°C. Samples were subsequently washed and secondary antibody mix added to each condition for 45 minutes at room temperature. Cells were washed and cytospinning carried out. Slides were dried for 10 minutes at RT before mounting with Vectashield Hardset mountant with DAPI (Vector Laboratories, H-1500) to stain DNA. Images were collected on a Leica SP5 CLSM with 100x (NA1.4) Plan-apochromatic objective using LAS-AF software (Version2, Leica) and processed using Adobe Photoshop (CS6) Results: CLL cells were incubated with anti-IgM- or control-antibody-coated latex beads for 3 hours before being placed on ice and stained with an AlexaFluor488-labeled anti-goat antibody, fixed and then analysed by confocal microscopy. CellMask Deep Red and DAPI were used to stain the plasma membrane and nucleus, respectively. Merged images are shown. A Z stack was collected of cells showing staining on beads that remained outside of cells, but no staining on beads that had been internalised. Fig 34 Method: Cells were collected following experimental conditions and fixed in 4% paraformaldehyde solution for 15 minutes on ice. Permeabilisation was carried out in 0.25% Triton/PBS for 10 minutes at room temperature where required for intracellular stains. Cells were then incubated in relevant primary antibody overnight at 4°C. Samples were subsequently washed and secondary antibody mix added to each condition for 45 minutes at room temperature. Cells were washed and cytospinning carried out. Slides were dried for 10 minutes at RT before mounting with Vectashield Hardset mountant with DAPI (Vector Laboratories, H-1500) to stain DNA. Images were collected on a Leica SP5 CLSM with 100x (NA1.4) Plan-apochromatic objective using LAS-AF software (Version2, Leica) and processed using Adobe Photoshop (CS6) Results: CLL samples were treated with anti-IgM- or control antibody-coated beads, or incubated in standard or starvation culture conditions for 24 hours in the absence of HCQ. Cells were fixed and stained for LAMP1 (red), LC3B (green) and nuclei (blue) and analysed by confocal microscopy. Images show LAMP1 and LC3B staining alone and merged images with all three colours. LAMP1/LC3B co-localisation is shown in merged images as yellow. Results show representative fields from a single sample. White arrows show co-localisation of LAMP/LC3B, red arrows show Dynabeads. Fig 35 Method: Cells were collected following experimental conditions and fixed in 4% paraformaldehyde solution for 15 minutes on ice. Permeabilisation was carried out in 0.25% Triton/PBS for 10 minutes at room temperature where required for intracellular stains. Cells were then incubated in relevant primary antibody overnight at 4°C. Samples were subsequently washed and secondary antibody mix added to each condition for 45 minutes at room temperature. Cells were washed and cytospinning carried out. Slides were dried for 10 minutes at RT before mounting with Vectashield Hardset mountant with DAPI (Vector Laboratories, H-1500) to stain DNA. Images were collected on a Leica SP5 CLSM with 100x (NA1.4) Plan-apochromatic objective using LAS-AF software (Version2, Leica) and processed using Adobe Photoshop (CS6) Results: CLL samples were treated with anti-IgM- or control antibody-coated beads, or incubated in standard or starvation culture conditions for 24 hours in the presence of HCQ (10 µM) for the last hour of this incubation. Cells were fixed and stained for LAMP1 (red), LC3B (green) and nuclei (blue) and analysed by confocal microscopy. Images show LAMP1 and LC3B staining alone and merged images with all three colours. LAMP1/LC3B co-localisation is shown in merged images as yellow. Results show representative fields from a single sample. White arrows show co-localisation of LAMP/LC3B, red arrows show Dynabeads. Fig 36 Method: Cells were collected following experimental conditions and fixed in 4% paraformaldehyde solution for 15 minutes on ice. Permeabilisation was carried out in 0.25% Triton/PBS for 10 minutes at room temperature where required for intracellular stains. Cells were then incubated in relevant primary antibody overnight at 4°C. Samples were subsequently washed and secondary antibody mix added to each condition for 45 minutes at room temperature. Cells were washed and cytospinning carried out. Slides were dried for 10 minutes at RT before mounting with Vectashield Hardset mountant with DAPI (Vector Laboratories, H-1500) to stain DNA. Images were collected on a Leica SP5 CLSM with 100x (NA1.4) Plan-apochromatic objective using LAS-AF software (Version2, Leica) and processed using Adobe Photoshop (CS6) Results: CLL samples were treated with anti-IgM-coated bead for 24 hours (with HCQ (10 µM) added for the last hour of this incubation). Cells were fixed and stained for LC3B (green) and nuclei (blue) and analysed by confocal microscopy. Image shows a high magnification of merged images with all three colour channels for LC3B, DAPI and DynaBeads. Results show a representative field from two samples analysed. White arrows show apparent bead internalisation with LC3B in the cytoplasm surrounding the beads in some cases. Fig 41 Method: Cells were collected following experimental conditions and fixed in 4% paraformaldehyde solution for 15 minutes on ice. Permeabilisation was carried out in 0.25% Triton/PBS for 10 minutes at room temperature where required for intracellular stains. Cells were then incubated in relevant primary antibody overnight at 4°C. Samples were subsequently washed and secondary antibody mix added to each condition for 45 minutes at room temperature. Cells were washed and cytospinning carried out. Slides were dried for 10 minutes at RT before mounting with Vectashield Hardset mountant with DAPI (Vector Laboratories, H-1500) to stain DNA. Images were collected on a Leica SP5 CLSM with 100x (NA1.4) Plan-apochromatic objective using LAS-AF software (Version2, Leica) and processed using Adobe Photoshop (CS6) Results: CLL cells were incubated with anti-IgM- or control-antibody-coated latex beads for 3 hours before being placed on ice and stained with an AlexaFluor488-labeled anti-goat antibody, fixed and then analysed by confocal microscopy. CellMask Deep Red and DAPI were used to stain the plasma membrane and nucleus, respectively. Merged images are shown. Top panels show comparison of with anti-IgM- or control-antibody-coated latex beads. Bottom panel is a high magnification image for anti-IgM-coated latex beads with internalised beads (ie, negative for AlexaFluor488) indicated by arrows. Fig 42 Method: Cells were collected following experimental conditions and fixed in 4% paraformaldehyde solution for 15 minutes on ice. Permeabilisation was carried out in 0.25% Triton/PBS for 10 minutes at room temperature where required for intracellular stains. Cells were then incubated in relevant primary antibody overnight at 4°C. Samples were subsequently washed and secondary antibody mix added to each condition for 45 minutes at room temperature. Cells were washed and cytospinning carried out. Slides were dried for 10 minutes at RT before mounting with Vectashield Hardset mountant with DAPI (Vector Laboratories, H-1500) to stain DNA. Images were collected on a Leica SP5 CLSM with 100x (NA1.4) Plan-apochromatic objective using LAS-AF software (Version2, Leica) and processed using Adobe Photoshop (CS6) Results: CLL cells were incubated with anti-IgM- or control-antibody-coated latex beads for 3 hours before being placed on ice and stained with an AlexaFluor488-labeled anti-goat antibody, fixed and then analysed by confocal microscopy. CellMask Deep Red and DAPI were used to stain the plasma membrane and nucleus, respectively. Merged images are shown. Panel shows high magnification confocal images of internalised anti-IgM-coated latex beads, with internalised beads (ie, negative for AlexaFluor488) indicated by arrows. Fig 51 DESCRIPTION OF THE DATA: The heatmap shows supervised hierarchical clustering for the 1,000 most differentially expressed genes across all samples from the RNA seq data. This dataset shows the data from 6 CLL patient samples with the conditions: 6H DMSO Control + antibody 6H VPS34-IN1 + Control antibody 6H DMSO + bead immobilised anti-IgM 6H VPS34-IN1 + bead immobilised anti-IgM 24H DMSO Control + antibody 24H VPS34-IN1 + Control antibody 24H DMSO + bead immobilised anti-IgM 24H VPS34-IN1 + bead immobilised anti-IgM RNA Seq DGE DESCRIPTION OF THE DATA: Methods: CLL samples (n=6) were incubated with goat F(ab’)2 anti-human IgM or control antibody coated Dynabeads at a 2:1 bead to cell ratio for 6 or 24 hours. Total mRNA was isolated using the Promega reliaprep RNA extraction kit (Reliaprep RNA Cell Miniprep System, Catalogue Z6011, Promega, Southampton, UK) and quality control was performed on a fragment analyser (Fragment Analyzer, Advanced Analytical Technologies), with a RNA Integrity Number (RIN) cut-off of above 8.0 determined as acceptable quality. A table of all RNA samples sent for sequencing is provided in Appendix 2. RNA-seq was performed at the Oxford Genomics Centre (Oxford, UK) using Illumina TruSeq Library Prep kit V2 and Illumina Novaseq 6000 sequencing platform. Raw RNA-seq data(fastq files) was aligned data against the hg19 reference genome using BWA, and initial data quality control was performed using FastQC. Counts matrices were produced using HTseq-count and exported for differential expression analysis in EdgeR. Results: Transcriptomic data were fitted to multifactor GLM models and tested for differential expression using quasi-likelihood f-tests. Multiple testing correction was performed using the Benjamini-Hochberg procedure. Gene Pathway analysis was performed downstream of this using Ingenuity Pathway Analysis software (IPA; Qiagen). This dataset shows a summary of the differential gene expression profiles Treatment conditions in this file: IgM_6 = Bead immobilised anti- IgM treatment for 6H, with DMSO as a vehicle control VPS_6 = Control antibody with VPS34-IN1 treatment for 6H IgM_VPS_6 = Bead immobilised anti- IgM treatment for 6H, with VPS34-IN1 treatment IgM_24 = Bead immobilised anti- IgM treatment for 24H, with DMSO as a vehicle control VPS_24 = Control antibody with VPS34-IN1 treatment for 24H IgM_VPS_24 = Bead immobilised anti- IgM treatment for 24H, with VPS34-IN1 treatment RNA Seq DMSO_lgM ab_vs_DMSO_control ab_6hrs Methods: CLL samples (n=6) were incubated with goat F(ab’)2 anti-human IgM or control antibody coated Dynabeads at a 2:1 bead to cell ratio for 6 or 24 hours. Total mRNA was isolated using the Promega reliaprep RNA extraction kit (Reliaprep RNA Cell Miniprep System, Catalogue Z6011, Promega, Southampton, UK) and quality control was performed on a fragment analyser (Fragment Analyzer, Advanced Analytical Technologies), with a RNA Integrity Number (RIN) cut-off of above 8.0 determined as acceptable quality. A table of all RNA samples sent for sequencing is provided in Appendix 2. RNA-seq was performed at the Oxford Genomics Centre (Oxford, UK) using Illumina TruSeq Library Prep kit V2 and Illumina Novaseq 6000 sequencing platform. Raw RNA-seq data(fastq files) were aligned data against the hg19 reference genome using BWA, and initial data quality control was performed using FastQC. Counts matrices were produced using HTseq-count and exported for differential expression analysis in EdgeR. Results: Transcriptomic data were fitted to multifactor GLM models and tested for differential expression using quasi-likelihood f-tests. Multiple testing correction was performed using the Benjamini-Hochberg procedure. Gene Pathway analysis was performed downstream of this using Ingenuity Pathway Analysis software (IPA; Qiagen). This dataset shows results from the comparison of the conditions DMSO Control antibody treatment for 6H versus DMSO bead-immobilised anti-IgM treatment for 6H This summarises the degree to which anti-IgM stimulation changes expression of each gene shown at 6H RNA Seq DMSO_lgM ab_vs_DMSO_control ab_24hrs DESCRIPTION OF THE DATA: Methods: CLL samples (n=6) were incubated with goat F(ab’)2 anti-human IgM or control antibody coated Dynabeads at a 2:1 bead to cell ratio for 6 or 24 hours. Total mRNA was isolated using the Promega reliaprep RNA extraction kit (Reliaprep RNA Cell Miniprep System, Catalogue Z6011, Promega, Southampton, UK) and quality control was performed on a fragment analyser (Fragment Analyzer, Advanced Analytical Technologies), with a RNA Integrity Number (RIN) cut-off of above 8.0 determined as acceptable quality. A table of all RNA samples sent for sequencing is provided in Appendix 2. RNA-seq was performed at the Oxford Genomics Centre (Oxford, UK) using Illumina TruSeq Library Prep kit V2 and Illumina Novaseq 6000 sequencing platform. Raw RNA-seq data(fastq files) were aligned data against the hg19 reference genome using BWA, and initial data quality control was performed using FastQC. Counts matrices were produced using HTseq-count and exported for differential expression analysis in EdgeR. Results: Transcriptomic data were fitted to multifactor GLM models and tested for differential expression using quasi-likelihood f-tests. Multiple testing correction was performed using the Benjamini-Hochberg procedure. Gene Pathway analysis was performed downstream of this using Ingenuity Pathway Analysis software (IPA; Qiagen). This dataset shows results from the comparison of the conditions DMSO Control antibody treatment for 24H versus DMSO bead-immobilised anti-IgM treatment for 24H This summarises the degree to which anti-IgM stimulation changes expression of each gene shown at 24H RNA Seq VPS34lN1_control ab_vs_DMSO_control ab_6hrs DESCRIPTION OF THE DATA: Methods: CLL samples (n=6) were incubated with goat F(ab’)2 anti-human IgM or control antibody coated Dynabeads at a 2:1 bead to cell ratio for 6 or 24 hours. Total mRNA was isolated using the Promega reliaprep RNA extraction kit (Reliaprep RNA Cell Miniprep System, Catalogue Z6011, Promega, Southampton, UK) and quality control was performed on a fragment analyser (Fragment Analyzer, Advanced Analytical Technologies), with a RNA Integrity Number (RIN) cut-off of above 8.0 determined as acceptable quality. A table of all RNA samples sent for sequencing is provided in Appendix 2. RNA-seq was performed at the Oxford Genomics Centre (Oxford, UK) using Illumina TruSeq Library Prep kit V2 and Illumina Novaseq 6000 sequencing platform. Raw RNA-seq data(fastq files) were aligned data against the hg19 reference genome using BWA, and initial data quality control was performed using FastQC. Counts matrices were produced using HTseq-count and exported for differential expression analysis in EdgeR. Results: Transcriptomic data were fitted to multifactor GLM models and tested for differential expression using quasi-likelihood f-tests. Multiple testing correction was performed using the Benjamini-Hochberg procedure. Gene Pathway analysis was performed downstream of this using Ingenuity Pathway Analysis software (IPA; Qiagen). This dataset shows results from the comparison of the conditions VPS34-IN1 with Control antibody treatment for 6H versus DMSO with control antibody treatment for 6H This summarises the degree to which VPS34 treatment changes expression of each gene shown at 6H RNA Seq VPS34lN1_control ab_vs_DMSO_control ab_24hrs DESCRIPTION OF THE DATA: Methods: CLL samples (n=6) were incubated with goat F(ab’)2 anti-human IgM or control antibody coated Dynabeads at a 2:1 bead to cell ratio for 6 or 24 hours. Total mRNA was isolated using the Promega reliaprep RNA extraction kit (Reliaprep RNA Cell Miniprep System, Catalogue Z6011, Promega, Southampton, UK) and quality control was performed on a fragment analyser (Fragment Analyzer, Advanced Analytical Technologies), with a RNA Integrity Number (RIN) cut-off of above 8.0 determined as acceptable quality. A table of all RNA samples sent for sequencing is provided in Appendix 2. RNA-seq was performed at the Oxford Genomics Centre (Oxford, UK) using Illumina TruSeq Library Prep kit V2 and Illumina Novaseq 6000 sequencing platform. Raw RNA-seq data(fastq files) were aligned data against the hg19 reference genome using BWA, and initial data quality control was performed using FastQC. Counts matrices were produced using HTseq-count and exported for differential expression analysis in EdgeR. Results: Transcriptomic data were fitted to multifactor GLM models and tested for differential expression using quasi-likelihood f-tests. Multiple testing correction was performed using the Benjamini-Hochberg procedure. Gene Pathway analysis was performed downstream of this using Ingenuity Pathway Analysis software (IPA; Qiagen). This dataset shows results from the comparison of the conditions VPS34-IN1 with Control antibody treatment for 24H versus DMSO with control antibody treatment for 24H This summarises the degree to which VPS34 treatment changes expression of each gene shown at 24H in response to anti-IgM stimulation RNA Seq VPS34lN1_lgM ab_vs_DMSO_control ab_6hrs DESCRIPTION OF THE DATA: Methods: CLL samples (n=6) were incubated with goat F(ab’)2 anti-human IgM or control antibody coated Dynabeads at a 2:1 bead to cell ratio for 6 or 24 hours. Total mRNA was isolated using the Promega reliaprep RNA extraction kit (Reliaprep RNA Cell Miniprep System, Catalogue Z6011, Promega, Southampton, UK) and quality control was performed on a fragment analyser (Fragment Analyzer, Advanced Analytical Technologies), with a RNA Integrity Number (RIN) cut-off of above 8.0 determined as acceptable quality. A table of all RNA samples sent for sequencing is provided in Appendix 2. RNA-seq was performed at the Oxford Genomics Centre (Oxford, UK) using Illumina TruSeq Library Prep kit V2 and Illumina Novaseq 6000 sequencing platform. Raw RNA-seq data(fastq files) were aligned data against the hg19 reference genome using BWA, and initial data quality control was performed using FastQC. Counts matrices were produced using HTseq-count and exported for differential expression analysis in EdgeR. Results: Transcriptomic data were fitted to multifactor GLM models and tested for differential expression using quasi-likelihood f-tests. Multiple testing correction was performed using the Benjamini-Hochberg procedure. Gene Pathway analysis was performed downstream of this using Ingenuity Pathway Analysis software (IPA; Qiagen). This dataset shows results from the comparison of the conditions VPS34-IN1 with bead-immobilised anti-IgM treatment for 6H versus DMSO with control antibody treatment for 6H This summarises the degree to which VPS34 treatment with anti IgM stimulation changes expression of each gene shown at 6H RNA Seq VPS34lN1_lgM ab_vs_DMSO_control ab_24hrs DESCRIPTION OF THE DATA: Methods: CLL samples (n=6) were incubated with goat F(ab’)2 anti-human IgM or control antibody coated Dynabeads at a 2:1 bead to cell ratio for 6 or 24 hours. Total mRNA was isolated using the Promega reliaprep RNA extraction kit (Reliaprep RNA Cell Miniprep System, Catalogue Z6011, Promega, Southampton, UK) and quality control was performed on a fragment analyser (Fragment Analyzer, Advanced Analytical Technologies), with a RNA Integrity Number (RIN) cut-off of above 8.0 determined as acceptable quality. A table of all RNA samples sent for sequencing is provided in Appendix 2. RNA-seq was performed at the Oxford Genomics Centre (Oxford, UK) using Illumina TruSeq Library Prep kit V2 and Illumina Novaseq 6000 sequencing platform. Raw RNA-seq data(fastq files) were aligned data against the hg19 reference genome using BWA, and initial data quality control was performed using FastQC. Counts matrices were produced using HTseq-count and exported for differential expression analysis in EdgeR. Results: Transcriptomic data were fitted to multifactor GLM models and tested for differential expression using quasi-likelihood f-tests. Multiple testing correction was performed using the Benjamini-Hochberg procedure. Gene Pathway analysis was performed downstream of this using Ingenuity Pathway Analysis software (IPA; Qiagen). This dataset shows results from the comparison of the conditions VPS34-IN1 with bead-immobilised anti-IgM treatment for 24H versus DMSO with control antibody treatment for 24H This summarises the degree to which VPS34 treatment with anti IgM stimulation changes expression of each gene shown at 24H Table of CLL samples used (Appendix 1) Table of all CLL samples used in this research. Sample ID refers to the ID given to each patient sample, with the letter after sample ID number referring to subsequent samples taken from the same patient. Clinical diagnosis refers to a clinical diagnosis of CLL being given. Tumour population % was measuredby the percent of cells in each sample that were CD5/CD19 +ve. sIgM levels were measure by flow cytometry, along with intracellular calcium signalling response (iCa). IGHV mutational status was analysed for each sample, along with the V gene and allele. Table of RNA QC results (Appendix 2) DESCRIPTION OF THE DATA: Method: CLL samples (n=6) were incubated with goat F(ab’)2 anti-human IgM or control antibody coated Dynabeads at a 2:1 bead to cell ratio for 6 or 24 hours. Total mRNA was isolated using the Promega reliaprep RNA extraction kit (Reliaprep RNA Cell Miniprep System, Catalogue Z6011, Promega, Southampton, UK) and quality control was performed on a fragment analyser (Fragment Analyzer, Advanced Analytical Technologies), with a RNA Integrity Number (RIN) cut-off of above 8.0 determined as acceptable quality. A table of all RNA samples sent for sequencing is provided here along with their RIN score. RNA-seq was performed at the Oxford Genomics Centre (Oxford, UK) using Illumina TruSeq Library Prep kit V2 and Illumina Novaseq 6000 sequencing platform. Top 100 IPA pathways from RNA seq data (appendix 3) ESCRIPTION OF THE DATA: Method: CLL samples (n=6) were incubated with goat F(ab’)2 anti-human IgM or control antibody coated Dynabeads at a 2:1 bead to cell ratio for 6 or 24 hours. Total mRNA was isolated using the Promega reliaprep RNA extraction kit (Reliaprep RNA Cell Miniprep System, Catalogue Z6011, Promega, Southampton, UK) and quality control was performed on a fragment analyser (Fragment Analyzer, Advanced Analytical Technologies), with a RNA Integrity Number (RIN) cut-off of above 8.0 determined as acceptable quality. A table of all RNA samples sent for sequencing is provided here along with their RIN score. RNA-seq was performed at the Oxford Genomics Centre (Oxford, UK) using Illumina TruSeq Library Prep kit V2 and Illumina Novaseq 6000 sequencing platform. Raw RNA-seq data(fastq files) were analysed by Dr Dean Bryant, who aligned data against the hg19 reference genome using BWA, and initial data quality control was performed using FastQC. Counts matrices were produced using HTseq-count and exported for differential expression analysis in EdgeR. Transcriptomic data were fitted to multifactor GLM models and tested for differential expression using quasi-likelihood f-tests. Multiple testing correction was performed using the Benjamini-Hochberg procedure. Results: Gene Pathway analysis was performed using Ingenuity Pathway Analysis software (IPA; Qiagen). Shown here are the top 100 IPA pathways, with reference to 'anti-IgM (6/24H) up' meaning the extent to which anti-IgM treatment increases the specified genes at the given time point. Reference to 'anti-IgM (6/24H) down' meaning the extent to which anti-IgM treatment decreases the specified genes at the given time point. The top 100 differentially expressed genes for control DMSO vs anti-IgM DMSO at 6H and 24H, the top 100 differentially expressed genes control DMSO versus anti-IgM VPS34-IN1 at 6H and 24H, and the Top 100 differentially expressed genes for control antibody DMSO versus control antibody VPS34-IN1 at 6H and 24H are shown. This summarises data in Appendix 3-8, which are labelled in subheadings. Date of data collection: 1/10/2017 -1/10/2021 Information about geographic location of data collection: University of Southampton, Southampton General Hospital Site Licence:CC-BY-NC-ND Related projects/Funders: Cancer Research UK and the Medical Research Council Related publications: BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia Smith, L., Minton, A. R., Blunt, M., Karydis, L., Dutton, D., Rogers-broadway, K., Dobson, R., Liu, R., Norster, F., Hogg, E., Ashton-Key, M., Strefford, J., Jia, L., Efremov, D., G. Vignir, H., Johnson, P., Stevenson, F., Forconi, F., Cragg, M., Tumbarello, D. & 2 others, , 28 Aug 2019, In: Leukemia. 9 p. BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia, Leukemia volume 34, pages 640–644 (2020) DOI: https://doi.org/10.1038/s41375-019-0557-y B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells, Exploration of Targeted Anti-tumor therapy (2022) DOI: https://doi.org/10.37349/etat.2022.00070 Date that the file was created: 05/2022 -------------- 4. Remove these notes before saving